Ambulatory Blood Pressure Monitoring

William White

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

CT Coronary Calcium Scoring, Hard Plaque and Soft Plaque Visualizati…

Scripps Health

M. Budoff

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn